循环肿瘤细胞预测DLL3双特异性抗体Tarlatamab的疗效
Tarlatamab是一种靶向DLL3的双特异性抗体,在SCLC中有效但疗效差异大且缺乏生物标志物。单细胞RNA测序显示SCLC活检中DLL3表达异质,分析循环肿瘤细胞(CTC)可将患者分为DLL3高或低表达。在前瞻性20例队列中,治疗前CTC的DLL3表达预测tarlatamab临床获益(敏感性85%,特异性100%)。
要点
- 治疗前CTC中DLL3表达可预测tarlatamab临床获益,敏感性85%、特异性100%。
- ≥25% DLL3阳性CTC的患者更可能从tarlatamab获益,低于此比例者罕见响应。
- 获得性耐药可表现为DLL3表达丢失或其他可靶向神经内分泌表位持续。
核心结论
- CTC中DLL3定量可识别可能从tarlatamab获益的患者,纵向监测可能指导获得性耐药时的治疗决策。
研究设计与样本
- 前瞻性队列研究,纳入20例患者,分析SCLC活检单细胞RNA测序及CTC。
主要发现
- SCLC活检中DLL3表达存在异质性,CTC分析可将患者分为DLL3高或低表达。
- 治疗前CTC的DLL3表达预测tarlatamab临床获益,敏感性85%、特异性100%。
- 血液中出现坏死性CTC簇伴随治疗诱导的肿瘤溶解。
- 部分获得性耐药病例与DLL3表达丢失但其他可靶向神经内分泌表位持续相关。
- 另一些患者CTC保留DLL3但伴有系统性T细胞功能障碍标志物。
关键数值与推荐
- ≥25% DLL3阳性CTC的患者从靶向该表位的双特异性抗体获得临床获益,低于此比例者罕见响应。
临床怎么用
- 可通过CTC无创定量免疫治疗靶向的表位,用于患者分层。
- 治疗前CTC的DLL3评分可能帮助选择适合抗体介导治疗的患者。
- 纵向CTC监测可在获得性耐药时辅助治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The bispecific antibody tarlatamab recruits T cells to cancers expressing the neuroendocrine epitope delta-like ligand 3 (DLL3). Tarlatamab is effective in small cell lung cancer (SCLC), but clinical outcomes vary, and no biomarkers enable patient selection. Single-cell RNA sequencing of SCLC biopsies identifies heterogeneity in DLL3 expression, and analysis of circulating tumor cells (CTC) distinguishes individual patients as predominantly DLL3Pos or DLL3Low. In a prospective cohort of 20 patients, pretreatment DLL3 expression on CTCs predicts tarlatamab clinical benefit (85% sensitivity and 100% specificity). Necrotic CTC clusters in blood accompany treatment-induced tumor lysis. Acquired resistance to tarlatamab is associated in some cases with loss of DLL3 expression but persistence of other targetable neuroendocrine epitopes; in other patients, DLL3 is retained on CTCs but accompanied by systemic markers of T-cell dysfunction. Quantitation of DLL3-positive CTCs identifies patients likely to benefit from tarlatamab, and longitudinal monitoring may guide therapeutic decision-making at the time of acquired resistance. SIGNIFICANCE: CTCs are abundant in SCLC, allowing noninvasive quantitation of epitopes targeted by immune therapies. Patients with at least 25% DLL3-positive CTCs derive clinical benefit from a bispecific antibody targeting this epitope; those with a lower fraction rarely respond. CTC scoring may thus enable stratification of patients for antibody-mediated therapeutics.
引用
- Mishra A, Meador CB, Kikkeri K, et al. Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab. Cancer Discov. 2026. PMID: 41532856. doi:10.1158/2159-8290.CD-25-1483
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。